C059 | PATIENT REPORTED OUTCOMES FROM BRUIN CLL-321: A RANDOMIZED PHASE 3 TRIAL COMPARING PIRTOBRUTINIB TO IDELALISIB/RITUXIMAB OR BENDAMUSTINE/RITUXIMAB IN COVALENT BTKI PRETREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

Background: The phase 3, randomized trial BRUIN CLL-321 assessed the safety and efficacy of pirtobrutinib vs investigators choice (IC) of idelalisib+rituximab (IdelaR) or bendamustine+rituximab (BR) in patients (pts) with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) pre-treated...

Descripció completa

Dades bibliogràfiques

Autors principals:	P. Ghia, D. Rossi, E. Ferrant, F. De La Cruz Vicente, D. Maruyama, V. Banerji, P. Cobb, S. Namburi, R. Greil, A. Loubert, K. Creel, L.M. Hess, N. Payakachat, A.S. Ruppert, D. Wang, P. Abada, C.C. Leow, M. Hill, C.C. Coombs, P. Barr, J.P. Sharman
Format:	Artigo
Idioma:	Inglês
Publicat:	Ferrata Storti Foundation 2025-09-01
Col·lecció:	Haematologica
Accés en línia:	https://haematologica.org/article/view/12823
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!